Anaxago
VC Fund
Paris, France
Anaxago is a brand new crowdfunding platform dedicated to innovative companies. Anaxago aims at changing the traditional equity capital investment model. Their goal is to forget about the capitalistic-only and go for a truly sharing and participative investment model. Thanks to Anaxago, entrepreneurs can benefit from the financial support oftheir investors but also learn from the shareholders' experience, expertise and network. Each investor can take an active part to the company life and so be a part of a lively entrepreneurial adventure.They offer a small range of companies each month to their investors community. Startups and small companies are chosen with good care and have to go through a whole process of financial analysis. They also prefer to select companies with a real innovative value added. With Anaxago, young and small companies can find funding and support to grow and develop. They give them a chance to be the actors of tomorrow's growth and reboost their economy.Since its launch, Anaxago gathered 100 000 members and invested more than 130M€ funding more than 200 businesses.
- Total investments:
- 46
- Last investment:
- Lead investor:
- 24%
- Fund size:
- $11M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Anaxago invests in
Stages Anaxago invests in
Countries Anaxago invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 10 contacts → | |||
Round size
- Seed
- $620k–$2.7M
- Series A
- $1.3M–$13M
- Venture - Series Unknown
- $1.5M–$3.3M
Investment Focus
Industry
- Biotechnology 7 (15%)
- SaaS 6 (13%)
- Software 4 (9%)
- Health Care 4 (9%)
- Real Estate 4 (9%)
Stage
- Seed 14 (30%)
- Series A 13 (28%)
- Venture - Series Unknown 5 (11%)
- Series B 4 (9%)
- Series C 2 (4%)
Country
- France 30 (65%)
- Belgium 1 (2%)
- Cameroon 1 (2%)
- United States 1 (2%)
- United Kingdom 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alexandre Heraud
Investment Director
|
Investment Director | Total investments: 46 | Find email | |
Stéphane Diagne
Developer
|
Developer | Total investments: 1 | Find email | |
Antoine Griffon
Technical director
|
Technical director | Total investments: 0 | Find email | |
Audrey Gauthier
Digital Head
|
Digital Head | Total investments: 0 | Find email | |
Caroline Lamaud
Co-Founder and Head of Brand Marketing & Communications
|
Co-Founder and Head of Brand Marketing & Communications | Total investments: 0 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| In Brittany, in Rennes Check & Visit was born from the desire to help the owners of the whole world to realize the conditions of their apartment. In France each year, there are over 3,400,000 inventories made. For the 2,500,000 owners, which they are part of it is not always easy to make the inventory of his apartment. Whether due to lack ofavailability, legal knowledge, or the reliability of paper status reports. The inventory quickly becomes a tedious and time-consuming task that any owner would like to do without. | $13.4M / Series A / May 26, 2023 | ||
| Posos is a clinical support platform optimizing healthcare professionals’ decisions at every step of the patient journey thanks to an AI-based cross-referencing search engine. Posos allows healthcare professionals to conduct simultaneous research on several drugs and to contextualize answers based on patient data | $9.7M / Series A / Oct 10, 2022 | ||
| PEP-Therapy is a biotechnology company developing first-in-class peptides as targeted therapies for severe diseases, with an initial focus on cancer. PEP-Therapy develops Cell Penetrating and Interfering Peptides (CP&IP) for the intracellular delivery of targeted therapies. These active compounds penetrate cells and block relevantintracellular protein-protein interactions, thus inhibiting key pathological mechanisms. | $1.9M / Series A / Jul 19, 2021 | ||
| Xenothera is a xenotherapy platform with embedded technology that renovates immunological treatments. Xenothera creates new therapeutic modes in numerous domains from immunomodulation to infectious diseases.Xenothera's technological platform is built on a double expertise of animal genetics and mastery of immunology processes. It renovatespassive immunotherapy by marketing a new generation of hyperimmune polyclonal sera.Xenothera’s platform ensures short-time development thanks to their mastery of the entire process, from animal genetics, choice of the immunogen, selection, and purification of interesting immunoglobulins, and access to market authorization in accelerated timescale. | $21.2M / Series C / Jun 29, 2021 | ||
| OCUS enables the world’s largest companies to seize the power and performance of visual content to grow their businesses and delight their customers. OCUS combines its technology with its creative community of 30,000 to deliver brand imagery at scale. | $24M / Series B / Apr 21, 2021 | ||
| Imageens develops a Web AI-Based platform for medical images analysis that empower professionals Imaging productivity by providing faster processing as well as more accurate and reliable reporting. | $1.4M / Seed / Apr 15, 2021 | ||
| SweepBright transforms the real estate sales flow into a fully digital journey. Its rich stack of features empowers real estate agencies of any kind to become far more efficient and deliver exceptional customer experiences. It has been designed from the onset with mobile usage in mind and integrates seamlessly with third-party applications. Thisenables agencies large or small, to transform their sales flow into a fully digital journey.It was founded in 2016 and is based in Antwerp, Belgium. | $3M / Series A / Dec 03, 2020 | ||
| BulldozAIR, Y Combinator and STATION F backed startup, is a construction project management platform used by large generalist corporates to collaborate with their construction contractors and monitor the progress of their construction projects from their office. This web and mobile platform is used by industry leaders worldwide from real estate,energy, retail, transportation, infrastructure, and manufacturing. Some clients include such as Carrefour, Total, Air Liquide, Vinci, Bouygues, Arkema, CHANEL and SNCF to name a few. BulldozAIR is based in Station F, the biggest startup incubator in the world and it operates internationally. | $4.7M / Series A / Nov 01, 2020 | ||
| Osivax is a developer of immunotherapy vaccines intended to facilitate the treatment of infectious diseases. The company's vaccines expedite the uptake into dendritic cells and increase the immunogenicity of the natural protein to trigger a more effective immune response, including an unprecedented CD8 T cell activation, enabling medicalpractitioners to treat patients with cancer as well as influenza, malaria and other infectious diseases effectively. | $17M / Series B / Jul 08, 2020 | ||
| Founded in 2009 by Philippe Bencteux, MD, Robocath designs, develops and commercializes robotic solutions to treat cardiovascular diseases. As an active player in the evolving medical robotic industry, these innovative solutions aim to make medical procedures safer, thanks to reliable technologies, while complementing manual interventions.R-One™is the first solution developed by Robocath. It uses a unique technology that optimizes the safety of robotic-assisted coronary angioplasty. It is designed to operate with precision and perform specific movements creating better interventional conditions. Thanks to its open architecture, R-One™ is compatible with market leading devices and cath labs.Robocath aims to become the world leader in vascular robotics and develop the remote treatment of vascular emergencies, guaranteeing the best care pathway for all. | $43.5M / Series C / Apr 29, 2020 | ||
| See all 46 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Anaxago invest in?
Anaxago invests primarily in Biotechnology, SaaS and Software startups, most often at Seed and Series A stage. Most of the 46 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Anaxago's check size?
Anaxago typically joins rounds of $620k–$2.7M at Seed, $1.3M–$13M at Series A and $1.5M–$3.3M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Anaxago participates in.
How do I contact Anaxago?
Public channels for Anaxago include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Anaxago?
The team at Anaxago includes Alexandre Heraud (Investment Director), Stéphane Diagne (Developer) and Antoine Griffon (Technical director), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
